Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Biden to release 1 million barrels of gasoline in bid to lower prices at pump
WASHINGTON (AP) — The Biden administration said Tuesday that it is releasing 1 million barrels of ga2024-05-22HK$3.5 billion Hong Kong Palace Museum opens after typhoon delay
The Hong Kong Palace Museum opened its doors to the public on Sunday, following a day’s delay2024-05-22After Berlin, Zelensky signs French security pact amid Navalny shock
By Alexander Ratz, Yuliia Dysa and Michel RoseFrance's President Emmanuel Macron (R) shakes hands wi2024-05-22- It's surely the ultimate coffee-table book.Café Cool: Feel-good Inspiring Designs, by Robert Schneid2024-05-22
- PRAGUE (AP) — Dylan Cozens scored a short-handed goal in overtime for Canada to edge the Czech Repub2024-05-22
Blooming wonderful: Britain's best springtime escapes, from award
Buds are turning to blossoms, bulbs to blooms and birds are singing in the hedgerows.It’s not just g2024-05-22
atest comment